Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer (original) (raw)
Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients
Kurt Ulm, Marinus Blankenstein
JNCI Journal of the National Cancer Institute, 2002
View PDFchevron_right
Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1
Fred C. G. J. Sweep
JNCI Journal of the National Cancer Institute, 2001
View PDFchevron_right
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)
Manfred Schmitt
Cancer research, 2002
View PDFchevron_right
Enhanced Benefit from Adjuvant Chemotherapy in Breast Cancer Patients Classified High-Risk according to Urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor Type 1 (n 3424)1
Marion Kiechle
2000
View PDFchevron_right
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
Rajko Kavalar
Radiology and Oncology, 2014
View PDFchevron_right
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node–negative breast carcinoma
A. Geurts-Moespot
Cancer, 2004
View PDFchevron_right
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer
Peter Andreasen
Cancer research, 1990
View PDFchevron_right
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine
Adel Gouri
Biomarker Insights, 2016
View PDFchevron_right
Plasminogen Activator Inhibitor Type 1 is the Most Significant of the Usual Tissue Prognostic Factors in Node-Negative Breast Ductal Adenocarcinoma Independent of Urokinase-Type Plasminogen Activator
Jean Rony Andre
Clinical Breast Cancer, 2008
View PDFchevron_right
The complex between urokinase-type plasminogen activator (PA) and its type-1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer
A. Geurts-Moespot
Thrombosis and Haemostasis, 2003
View PDFchevron_right
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
Karin Milde-langosch, T. Karn
OncoTargets and Therapy, 2014
View PDFchevron_right
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and …
Serenella Eppenberger-Castori
JNCI Journal of the …, 2002
View PDFchevron_right
Urokinase-Plasminogen Activator, a New and Independent Prognostic Marker in Breast Cancer1
Peter Andreasen
2000
View PDFchevron_right
Urokinase plasminogen activator: a prognostic marker in breast cancer including …
Enda McDermott
Clinical …, 1998
View PDFchevron_right
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
Christian Rosenquist
Cancer research, 1993
View PDFchevron_right
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
Michael P Kramer
Cancer research, 2000
View PDFchevron_right
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
lothar pache
Breast Cancer Research and Treatment, 1993
View PDFchevron_right
Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 mRNA Assessment in Breast Cancer by Means of NASBA: Correlation With Protein Expression
Alejandro Cuellar
American Journal of Clinical Pathology, 2007
View PDFchevron_right
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers
Michael Duffy
Biochemical Society Transactions, 2002
View PDFchevron_right
Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 mRNA Assessment in Breast Cancer by Means of NASBA
Alejandro Bravo Cuellar
American Journal of Clinical Pathology, 2007
View PDFchevron_right
Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
Enda McDermott, Niall OHiggins
Journal of Surgical Oncology, 1999
View PDFchevron_right
Predictive Impact of Urokinase-Type Plasminogen Activator
Fred C. G. J. Sweep
Cancer Research, 2004
View PDFchevron_right
Prognostic significance of the urokinase type plasminogen activator (u-PA) system in node-negative breast cancer
kim myung jin
Breast Cancer, 1999
View PDFchevron_right
Urokinase-Type Plasminogen Activator System in Breast Cancer
Michael Duffy
Cancer Research, 2004
View PDFchevron_right
Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance
James Wittliff
Journal of Clinical Laboratory Analysis, 2012
View PDFchevron_right
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts
Manfred Schmitt
British journal of cancer, 1998
View PDFchevron_right
Plasminogen activator inhibitor type 2 in breast cancer
Niall OHiggins
British journal of cancer, 1997
View PDFchevron_right
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer
Ross Stephens
Clinical cancer research : an official journal of the American Association for Cancer Research, 2002
View PDFchevron_right
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
Niall OHiggins
International Journal of Cancer, 1995
View PDFchevron_right
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA
Viktor Magdolen
International Journal of Molecular Medicine, 2008
View PDFchevron_right
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
Michael Duffy
Breast cancer research : BCR, 2014
View PDFchevron_right
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel
Gunter Von Minckwitz
BMC Cancer, 2011
View PDFchevron_right
Increased Expression of Urokinase-Type Plasminogen Activator mRNA Determines Adverse Prognosis in ErbB2-Positive Primary Breast Cancer
Pratyaksha Wirapati
Journal of Clinical Oncology, 2006
View PDFchevron_right